# Progress Note 06 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Louis (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX002-SYN-TD
- Date: 1969-09-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Desmond Achterberg-Cole, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Ten-week review: remission, antipsychotic taper, cognition and the echocardiogram. **S**

## History of present illness

Mr. Louis returns one week after his preventive visit. He has had no persecutory beliefs for about six weeks and sleeps six to seven hours. In the last week of August he was out of town for four days of paid appearances and missed two urine tests; the day after he came home, with an old acquaintance, he used cocaine on one day. He reported it himself at his next test, which was positive, and all tests since have been negative. He had no psychotic symptoms after that use. His stool test kit came back negative. His home readings average 128/80 mmHg. The echocardiogram was done this morning. **S**

| Element | Detail |
|---|---|
| Cocaine | One day of use three weeks ago, reported by him; none since |
| Urine tests | Two missed while away; one positive after the lapse; the rest negative |
| Psychotic symptoms | None for six weeks, including after the lapse |
| Home blood pressure | Average 128/80 mmHg |
| Stool test | Negative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Neurological | Negative | No memory lapses, restlessness or tremor |
| Psychiatric | Negative | No persecutory beliefs; disappointed by the lapse but steady; no thoughts of suicide or of harming anyone |

4 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with fentanyl test strips and instruction for him and anyone he lives with **S**
- Aripiprazole 2 mg oral tablet, one tablet each morning for two weeks, then stop **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/82 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 102.1 kg; BMI 29.2 kg/m². All vital signs are synthetic.

Left ventricular ejection fraction (echocardiogram): 60%; MoCA: 27; PHQ-9: 3. All results are synthetic.

## Change since baseline

- MoCA: 25 at baseline, 27 at this visit **S**
- PHQ-9: 8 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 130/82, pulse 74; weight 102.1 kg, BMI 29.2 |
| Cardiovascular | Regular rhythm; no murmur; no ankle edema |
| Neurological | No tremor, rigidity or abnormal movements; no akathisia |
| Psychiatric | Calm and engaged; no delusional content; MoCA 27 |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cocaine use disorder, severe, with cocaine-induced psychotic disorder, psychosis in remission** (F14.250). Six weeks without psychotic symptoms. The ASAM/AAAP guideline advises a gradual taper off the antipsychotic after a period of remission when the psychosis was stimulant-induced, and he would like to stop. One day of cocaine use after a trip, reported by him; a return to use is common in recovery and is met without blame. MoCA 27 after ten weeks with good sleep and no psychotic symptoms, up from 25 during symptoms; with a normal MRI, there is no evidence of a neurocognitive disorder, and no research label such as traumatic encephalopathy syndrome is applied. Safety reviewed: no thoughts of suicide or of harming anyone. **S**
   - Aripiprazole 2 mg each morning for two weeks, then stop; call at once if the fears or sleeplessness return.
   - Continue contingency management to the end of twelve weeks and weekly therapy.
   - Travel plan: urine tests at a partner clinic and phone therapy sessions when away.
   - MoCA yearly.
2. **Hypertension on amlodipine** (I10). Echocardiogram: ejection fraction 60%, mild concentric left ventricular hypertrophy, normal valves, aortic root 3.6 cm and ascending aorta 3.5 cm, both normal. Clinic 130/82 and home average 128/80 mmHg: near target. **S**
   - Continue amlodipine 5 mg.
   - He was told that cocaine raises the risk of heart attack, stroke and tearing of the aorta, and to call 911 for chest or back pain.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Cocaine use since the last visit (his own account), cravings and triggers | Every visit | Completed today | One day of use about three weeks ago; none since |
| Laboratory | Urine drug tests in contingency management, with fentanyl, and prize draws for negative results | Twice weekly for twelve weeks, then at visits | Deferred | Two tests were missed while he was away for four days in late August, and he used cocaine on one day after returning; the next test was positive and all later tests negative. No lasting harm: he reported the use himself, had no psychotic symptoms and stopped at once. Corrective action: a travel plan with testing at a partner clinic and phone therapy sessions |
| Examination | Psychotic symptoms, insight and sleep | Every visit | Completed today | No psychotic symptoms for six weeks, including after the lapse |
| Medication safety | Antipsychotic safety: weight, blood pressure, akathisia (Barnes scale) and abnormal movements (AIMS) | Weight and akathisia at every visit while on treatment; AIMS at baseline and every six months | Completed today | Weight 102.1 kg, up 1.1 kg since starting; no akathisia or abnormal movements; taper to 2 mg today |
| Laboratory | Fasting glucose or hemoglobin A1c and lipids on an antipsychotic | Baseline, at four months, then yearly | Up to date | Baseline done; the four-month check will not be needed if aripiprazole stops as planned |
| Examination | Cognitive screen (MoCA) | At baseline and again once he is well and off cocaine | Completed today | MoCA 27, normal, after ten weeks well |
| Examination | Blood pressure in clinic and at home | Every visit; home readings before diagnosis and after each change | Completed today | Clinic 130/82; home average 128/80 mmHg on amlodipine |
| Imaging | Echocardiogram for stage 2 hypertension or left ventricular hypertrophy | At diagnosis | Completed today | Ejection fraction 60%; mild concentric left ventricular hypertrophy; aortic root 3.6 cm and ascending aorta 3.5 cm |
| Survey | Suicide and violence risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone after the lapse |
| Medication safety | Naloxone and fentanyl test strips on hand | Every visit | Completed today | Naloxone at home; he used a test strip the day of the lapse |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and every four weeks while in treatment | Completed today | PHQ-9 3, item 9 scored 0; PHQ-2 0 at the preventive visit |
| Self-management | Cognitive behavioral therapy | Weekly | Completed today | Eight of nine sessions attended; the missed one was during the trip |
| Self-management | Finances, social work and taxpayer services | Every visit | Completed today | Tax clinic appointment kept; awaiting their review |
| Self-management | Family involvement, only with his consent | Every visit | Completed today | No family contact requested by him |

## Goal progress

- Persecutory fears gone and six or more hours of sleep. Outcome by 1969-08-10: No persecutory beliefs by four weeks; sleeping six to seven hours. **S**
- No cocaine use, his goal, with contingency management and cognitive behavioral therapy. In progress; target 1969-10-26. **S**
- Blood pressure below 130/80 mmHg. In progress; target 1969-10-26. **S**
- A clear answer about his memory and thinking once he is well. Outcome by 1969-09-21: MoCA 25 during symptoms, 27 after ten weeks; brain MRI normal; no neurocognitive disorder. **S**
- A plan for money that lets him sleep. In progress; target 1969-10-26. **S**

## Medication changes

- Stopped: Aripiprazole 5 mg oral tablet, one tablet each morning **S**
- Started: Aripiprazole 2 mg oral tablet, one tablet each morning for two weeks, then stop **S**

## Guideline basis

- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2023), American Society of Addiction Medicine and American Academy of Addiction Psychiatry (Journal of Addiction Medicine 2024;18(1S Suppl 1):1-56)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia (2020), American Psychiatric Association (American Journal of Psychiatry 2020;177(9):868-872)
- Treatment for Stimulant Use Disorders (Treatment Improvement Protocol 33, updated 2021) (2021), Substance Abuse and Mental Health Services Administration
- National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021), Neurology 2021;96(18):848-863
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026), Aether Forge

## Follow-up

- Fifteen-week review in five weeks, after the taper. Contingency management to the end of twelve weeks; therapy weekly. Call the clinic or 988 if the fears or sleeplessness return. **S**
- Next scheduled visit 1969-10-26: fifteen-week review off the antipsychotic: recovery, blood pressure and finances. **S**
